A major pharmaceutical manufacturer’s sudden decision to withdraw anti-addiction drugs from Sweden has sparked urgent concern amongst healthcare professionals and government officials, raising questions about patient care and the fragility of European pharmaceutical supply chains.

US-based company Indivior has abruptly informed Swedish healthcare providers that it will stop selling Subutex and Suboxone, two medicines used to treat opioid use disorder, in the Swedish market. Furthermore, the Nasdaq-listed manufacturer also notified the Swedish Medical Products Agency (MPA) of the imminent anti-addiction drug withdrawal.

Five European Countries Affected

The dependency medication exit extends beyond Sweden. Indeed, in its third-quarter report for 2025, Indivior stated that it also plans to withdraw from the UK, Ireland, Finland and Italy. Meanwhile, the company’s subsidiary Indivior Europe Limited, which holds the market authorisation in Sweden, operates its head office in Dublin.

In a letter to care providers, the company explained that it has recently conducted a strategic review of its operations outside the United States. Consequently, after exploring several options, the manufacturer has decided to discontinue support for operations outside its priority markets.

Notably, the Swedish MPA has set specific deadlines for the anti-addiction drug withdrawal: Subutex will not be available in Sweden after 12 January 2026, whilst Suboxone will disappear from shelves after 15 December 2025.

Authorities Caught Off Guard

Eva Pettersson, group manager at the Department of Medicine Availability at the Swedish MPA, confirmed that the notification caught the agency off guard, as they received no advance signals from the manufacturer. Subsequently, the agency will now analyse the situation and start a dialogue with the manufacturer to persuade them to continue selling these products in Sweden.

Swedish Minister for Social Affairs Jakob Forssmed, who has pharmaceuticals in his portfolio, expressed concern about the sudden dependency medication exit. Moreover, he stated, “Swedish authorities have a mandate to work against shortages and residual situations. This is a typical example of a shortage situation when medicines disappear in this way.”

Replacement Challenges for Patients

The Subutex depot injection could prove particularly difficult to replace, as it is a long-acting injection that releases the drug slowly over time. Specifically, this formulation helps many patients with drug dependency, as they only need to take it once a month. Additionally, the Swedish National Board of Health and Welfare lists the Suboxone product as a critical medicine product.

“There is another approved preparation that doctors use for the same indication, but it is not directly interchangeable. Therefore, doctors will have to make individual reviews,” Pettersson explained.

Joar Guterstam, an addiction specialist at the Karolinska University hospital and a researcher in addiction medicine at the Karolinska Institutet, told Swedish media that the anti-addiction drug withdrawal surprised him greatly. “This is a type of treatment that has become quite popular and is the latest drug that regulators approved. Suddenly, it disappears,” he said.

Furthermore, Guterstam described the situation as “an emergency” and said doctors must now rethink their priorities and “quickly try out alternatives for the patients.”

Trade Policy Implications

Minister Forssmed pointed to the US administration’s trade strategy as a potential factor behind the dependency medication exit. Specifically, he noted, “We are now seeing rapid changes in the pharmaceutical sector as American policy really affects the pharmaceutical market in Europe. This is very worrying for us, and we need to work faster in this area.”

Additionally, the minister acknowledged that the Swedish pharmaceutical system needs improvement as it is very complex. “This is something we need to work on, and work on quickly. However, I think that we should be cautious and not read too much into this individual decision. But it is clearly worrying,” he added.

Industry Perspective on Market Exits

Bengt Mattson, senior adviser at LIF (the Swedish Association of Research-Based Pharmaceutical Companies), noted in general remarks that “there will always be situations in global competition where companies may prioritise one market over another.”

Moreover, Mattson explained that companies could face influence in such prioritisations by the US administration’s initiative on tariffs and the Most Favoured Nation campaign, which aims to secure lower prices for medicines in the US. Consequently, he predicted, “This will most likely have consequences on the market.”

Vulnerable Patients at Risk

The sudden anti-addiction drug withdrawal raises serious questions about continuity of care for vulnerable patients who depend on these medicines for their recovery. As a result, healthcare providers must now scramble to identify suitable alternatives and transition patients to different treatment regimens, a process that requires careful medical oversight and individualised assessment.

The situation highlights the vulnerability of European healthcare systems to pharmaceutical market decisions that commercial considerations rather than patient needs drive. Meanwhile, with deadlines fast approaching, Swedish healthcare providers face mounting pressure to ensure no patient is left without appropriate treatment options.

Furthermore, the dependency medication exit underscores broader concerns about medicine availability across Europe. Particularly, when manufacturers prioritise certain markets over others, patients in smaller markets become particularly vulnerable to supply disruptions that can have serious health consequences.

Swedish doctors particularly worry that heavy drug abusers will lack acceptable alternatives following the anti-addiction drug withdrawal. Specifically, the loss of long-acting depot formulations that require only monthly administration represents a significant setback for patient compliance and treatment outcomes.

Urgent Need for Solutions

The crisis highlights the fragile nature of pharmaceutical supply chains in Europe. In addition, it demonstrates how corporate decisions can rapidly undermine public health infrastructure that countries have carefully built over decades.

Healthcare professionals now face the difficult task of managing patient transitions during this dependency medication exit. Ultimately, they must balance clinical effectiveness with practical availability whilst ensuring that vulnerable individuals maintain access to life-saving treatments.

At the time of publication, Indivior’s media officials had not responded to requests for comment on the anti-addiction drug withdrawal and its implications for patient care across the five affected European markets.

Source: dbrecoveryresources